Revuforj revenue surges 144% to $48.9M on second FDA approval; net loss halves to $42.7M

Filed April 30, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 5, 2025 · ~2 min read

Key Changes

• high

  Revuforj revenue jumped 144% year-over-year to $48.9M in Q1 2026, driven by October 2025 FDA approval for a second indication (NPM1-mutated AML) and 160% prescription volume growth. Nearly half of KMT2A patients now proceed to transplant after treatment, up from 33%, extending treatment duration.

  MD&A: Revuforj Revenue & Clinical Use verify on EDGAR →
• high

  Net loss narrowed from $84.8M to $42.7M year-over-year as Niktimvo collaboration revenue reached $15.9M (vs. $0.2M loss in Q1 2025) and operating expenses declined. Cash position fell to $352.1M from $602.1M a year earlier, though management states runway is sufficient.

  MD&A: Financial Performance verify on EDGAR →
• high

  New risk factor warns that proposed FDA workforce reductions could delay clinical trial reviews and product approvals, reducing the agency's capacity to perform regulatory functions consistent with past practices.

  Risk Factors verify on EDGAR →